The acquired depigmenting disorder of vitiligo affects an estimated 1% of the world population and constitutes one of the commonest dermatoses. Although essentially asymptomatic, the psychosocial impact of vitiligo can be severe. The cause of vitiligo remains enigmatic, hampering efforts at successful therapy. The underlying pathogenesis of the pigment loss has, however, been clarified to some extent in recent years, offering the prospect of effective treatment, accurate prognosis and rational preventative strategies. Vitiligo occurs when functioning melanocytes disappear from the epidermis. A single dominant pathway is unlikely to account for all cases of melanocyte loss in vitiligo; rather, it is the result of complex interactions of biochemical, environmental and immunological events, in a permissive genetic milieu. ROS (reactive oxygen species) and H2O2 in excess can damage biological processes, and this situation has been documented in active vitiligo skin. Tyrosinase activity is impaired by excess H2O2 through oxidation of methionine residues in this key melanogenic enzyme. Mechanisms for repairing this oxidant damage are also damaged by H2O2, compounding the effect. Numerous proteins and peptides, in addition to tyrosinase, are similarly affected. It is possible that oxidant stress is the principal cause of vitiligo. However, there is also ample evidence of immunological phenomena in vitiligo, particularly in established chronic and progressive disease. Both innate and adaptive arms of the immune system are involved, with a dominant role for T-cells. Sensitized CD8+ T-cells are targeted to melanocyte differentiation antigens and destroy melanocytes either as the primary event in vitiligo or as a secondary promotive consequence. There is speculation on the interplay, if any, between ROS and the immune system in the pathogenesis of vitiligo. The present review focuses on the scientific evidence linking alterations in ROS and/or T-cells to vitiligo.
Skip Nav Destination
Article navigation
February 2011
Review Article|
October 20 2010
Vitiligo, reactive oxygen species and T-cells
Steven J. Glassman
1Division of Dermatology, Department of Medicine, University of Ottawa, 737 Parkdale Avenue, Ottawa, Ontario, Canada K1Y 1J8
Correspondence: Dr Steven J. Glassman (email sglassman@toh.on.ca).
Search for other works by this author on:
Clin Sci (Lond) (2011) 120 (3): 99–120.
Article history
Received:
November 23 2009
Revision Received:
August 26 2010
Accepted:
August 26 2010
Citation
Steven J. Glassman; Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond) 1 February 2011; 120 (3): 99–120. doi: https://doi.org/10.1042/CS20090603
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.